Enobosarm

Phase 2Small molecule

VVeru Inc.

Enobosarm is one of 67 small molecule programs targeting Weight loss. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossActive, not recruiting

Breast CancerActive, not recruiting

Obesity & OverweightRecruiting

Weight LossPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Obesity & OverweightPhase 2

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Enobosarm

VVeru Inc.

Phase 2

2 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Tianeptine

Pfizer

Preclinical

1 10

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Obesity & Overweight

NCT07446998

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02971761·18 enrolled

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated·VVeru Inc.·Phase 3·NCT04869943·52 enrolled

Chronic1 trial

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Completed·VVeru Inc.·Phase 2·NCT06282458·168 enrolled

Menopausal Women1 trial

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

Completed·UUnknown Sponsor·Phase 1·NCT03264651·9 enrolled

Obesity & Overweight1 trial

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

Recruiting·VVeru Inc.·Phase 2·NCT07446998·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Enobosarm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enobosarm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enobosarm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veru Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVeru Inc.

Enobosarm

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer2 trials

Chronic1 trial

Menopausal Women1 trial

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News